CRNX vs. VTRS, MRNA, RDY, PCVX, SRPT, QGEN, ASND, ROIV, RVMD, and LEGN
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.
Crinetics Pharmaceuticals vs.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Viatris has higher revenue and earnings than Crinetics Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viatris had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 3 mentions for Viatris and 2 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.00 beat Viatris' score of -0.20 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.
98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Crinetics Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
Crinetics Pharmaceuticals received 136 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 69.30% of users gave Crinetics Pharmaceuticals an outperform vote while only 35.48% of users gave Viatris an outperform vote.
Crinetics Pharmaceuticals currently has a consensus target price of $72.64, suggesting a potential upside of 93.82%. Viatris has a consensus target price of $13.67, suggesting a potential upside of 21.54%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Crinetics Pharmaceuticals is more favorable than Viatris.
Crinetics Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Crinetics Pharmaceuticals' return on equity.
Summary
Crinetics Pharmaceuticals beats Viatris on 11 of the 18 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRNX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CRNX Stock Alerts